Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Monte Rosa Therapeutics, Inc. (GLUE : NSDQ)

• Company Description    Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON. Number of Employees: 134

• Price / Volume Information    Yesterday's Closing Price: $4.73 Daily Weekly Monthly 20 Day Moving Average: 412,174 shares Shares Outstanding: 61.51 (millions) Market Capitalization: $290.94 (millions) Beta: 1.41 52 Week High: $12.40 52 Week Low: $3.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.60% -1.62% 12 Week 16.50% 2.09% Year To Date -31.84% -35.63%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 321 HARRISON AVENUE SUITE 900 - BOSTON,MA 02118 USA ph: 617-949-2643 fax: - ir@monterosatx.com http://www.monterosatx.com

• General Corporate Information    Officers Markus Warmuth - Chief Executive Officer; President Jennifer Champoux - Chief Operating Officer Edmund Dunn - Senior Vice President; Corporate Controller Ali Behbahani - Director Kimberly L. Blackwell - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 61225M102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 61.51 Most Recent Split Date: (:1) Beta: 1.41 Market Capitalization: $290.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.32 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.58 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 59.12 PEG Ratio: - Price Ratios Price/Book: 1.06 Price/Cash Flow: - Price / Sales: 1.82 EPS Growth vs. Year Ago Period: 207.55% vs. Previous Quarter: 147.83% Sales Growth vs. Year Ago Period: 7,882.05% vs. Previous Quarter: 40.04% ROE 06/30/25 - - 03/31/25 - 2.65 12/31/24 - -36.10 ROA 06/30/25 - - 03/31/25 - 1.65 12/31/24 - -21.31 Current Ratio 06/30/25 - - 03/31/25 - 5.61 12/31/24 - 2.40 Quick Ratio 06/30/25 - - 03/31/25 - 5.61 12/31/24 - 2.40 Operating Margin 06/30/25 - - 03/31/25 - 3.86 12/31/24 - -96.14 Net Margin 06/30/25 - - 03/31/25 - 3.86 12/31/24 - -96.14 Pre-Tax Margin 06/30/25 - - 03/31/25 - 5.93 12/31/24 - -92.74 Book Value 06/30/25 - - 03/31/25 - 4.47 12/31/24 - 3.63 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©